6,000 Shares in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Acquired by NJ State Employees Deferred Compensation Plan

NJ State Employees Deferred Compensation Plan purchased a new position in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,000 shares of the company’s stock, valued at approximately $263,000.

A number of other institutional investors have also recently modified their holdings of the stock. Legal & General Group Plc lifted its stake in Biohaven Pharmaceutical by 14.1% in the fourth quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock worth $196,000 after acquiring an additional 652 shares during the last quarter. Manchester Capital Management LLC purchased a new position in Biohaven Pharmaceutical in the first quarter worth approximately $52,000. American International Group Inc. lifted its stake in Biohaven Pharmaceutical by 6.5% in the first quarter. American International Group Inc. now owns 19,922 shares of the company’s stock worth $1,025,000 after acquiring an additional 1,216 shares during the last quarter. NumerixS Investment Technologies Inc lifted its stake in Biohaven Pharmaceutical by 333.3% in the first quarter. NumerixS Investment Technologies Inc now owns 2,600 shares of the company’s stock worth $134,000 after acquiring an additional 2,000 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Biohaven Pharmaceutical by 6.2% in the first quarter. New York State Common Retirement Fund now owns 36,216 shares of the company’s stock worth $1,864,000 after acquiring an additional 2,100 shares during the last quarter. Institutional investors own 90.92% of the company’s stock.

In other Biohaven Pharmaceutical news, CEO Vlad Coric acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The shares were acquired at an average cost of $40.22 per share, for a total transaction of $201,100.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John W. Childs acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was acquired at an average price of $40.37 per share, for a total transaction of $403,700.00. The disclosure for this purchase can be found here. Insiders purchased a total of 17,500 shares of company stock worth $712,425 over the last quarter. Insiders own 23.90% of the company’s stock.

BHVN traded down $1.59 during trading on Monday, hitting $39.67. The stock had a trading volume of 10,062 shares, compared to its average volume of 731,904. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -6.47 and a beta of 0.25. The business has a 50-day moving average of $44.66. Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $29.17 and a twelve month high of $67.86.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($1.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.50) by $0.09. During the same quarter last year, the firm earned ($2.32) EPS. Sell-side analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -6.26 EPS for the current year.

Several analysts have recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and set a $84.00 price objective (down previously from $89.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, June 25th. ValuEngine downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, June 19th. Needham & Company LLC boosted their price objective on shares of Biohaven Pharmaceutical to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Goldman Sachs Group assumed coverage on shares of Biohaven Pharmaceutical in a research report on Monday, May 6th. They set a “buy” rating and a $92.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $69.64.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: What is the role of the G-20?

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.